Alx Oncology Holdings (ALXO) Change in Accured Expenses (2019 - 2026)

Alx Oncology Holdings has reported Change in Accured Expenses for 8 years, with the latest figure at -$3.0 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 3005.15% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$913000.0 (up 92.16% YoY) and the FY2025 annual result came in at $2.0 million, up 115.86% from the prior year.
• Change in Accured Expenses fell to -$3.0 million in Q1 2026 per ALXO's latest filing, from -$2.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $8.3 million in Q3 2023 and troughed at -$10.9 million in Q4 2024.
• A 5-year average of $271588.2 and a median of -$97000.0 in 2025 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2026: Change in Accured Expenses soared 669.59% in 2023, then slumped 3005.15% in 2026.
• Over 5 years, Change in Accured Expenses stood at $615000.0 in 2022, then jumped by 669.59% to $4.7 million in 2023, then sank by 330.17% to -$10.9 million in 2024, then jumped by 80.28% to -$2.1 million in 2025, then slumped by 40.22% to -$3.0 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$3.0 million, -$2.1 million, and $6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.